"How plausible is it that Dirucotide has strong efficacy in SPMS but not in RRMS?"
That's a very good question and one I meant to raise in my last post but forgot. I am by no means an MS expert so I don't know all of the differences/similarities between those two patient populations (SPMS vs. RRMS) and how a given drug should react in those two populations. But, it's another fair question that has to raise some level of doubt for the drug.
I didn’t think SeekingAlpha could get any dumber, but it just did.
That guy should win the Nobel prize for economics. What he basically said was that he bought a stock and it went down. He will now learn from his mistake and wait before he gets fooled again.
Market Data 
Markets 
AI
